A landmark study in Diabetes Care reveals that soluble urokinase plasminogen activator receptor (suPAR) mediates over half of the increased risk for adverse cardiovascular outcomes in patients with diabetes and coronary artery disease, surpassing traditional inflammatory markers like hs-CRP.